> ## Content Index > Fetch the complete content index at: https://compoundcodex.org/llms.txt > Use this file to discover other available public pages before exploring further. # Modafinil for cognitive enhancement - URL: https://compoundcodex.org/modafinil/ - Published: 2026-08-25T15:43:57.000Z - Updated: 2026-08-25T15:53:13.000Z - Description: It works for the sleep disorders it is licensed to treat. Whether it makes a rested person think better is a different question, with a messier answer. - Author: The Archivist - Tags: nootropics, grade-moderate, verdict-mixed, modafinil Moderate evidence Mixed ⚑ Prescription only · Schedule IV Marks reviewed Aug 2026 6 sources cited Next review Aug 2027 --- ## Two different questions, two different answers Modafinil is approved, and it works — for what it is approved for. It reduces excessive sleepiness in narcolepsy, obstructive sleep apnoea and shift work disorder, and the evidence for that is solid enough that no serious person disputes it. That is not why most people take it. The claim this page grades is the other one: that modafinil makes an ordinary, adequately rested person think better. That question has been asked many times, mostly in small academic crossover studies, and the answers do not line up. ## What the enhancement research found The most cited synthesis pooled studies of modafinil in healthy, *non-sleep-deprived* volunteers.[1](#c1) Its conclusion was genuinely mixed, and both halves get quoted selectively depending on who is doing the quoting. #### What the review actually concluded Simple tasks — basic attention, reaction timelittle or no consistent benefit Complex tasks — executive function, learning, memorymore reliable benefit Mood, motivation and confidencefrequently improved Consistency across studiespoor Typical study sizesmall crossover designs The pattern that emerges is narrower than the headlines suggested. Where tasks are simple and short, modafinil mostly does not help a rested person. Where tasks are complex, extended and draw on several cognitive processes at once, benefits appear more reliably.[1](#c1) There is a plainer reading available, and it deserves stating: much of what modafinil reliably does is make effortful work feel less effortful. Improved mood, motivation and willingness to stay on task will raise performance on a long, boring test without altering the underlying faculty. "You will find it easier to keep going" and "you will think better" are different claims, and the second is the one being sold. Effect sizes are modest, the studies are small, and the literature carries the publication-bias problem common to any field where a positive finding is more interesting than a null one. ## Why the verdict is Mixed rather than Supported Our rubric records disagreement rather than averaging it away. Trials of modafinil in rested healthy adults point in different directions depending on the task tested, and that disagreement is not resolved by dose, population or duration — the three things that usually explain it. A Mixed verdict caps evidence strength at Moderate under our scale, however large the literature grows. That cap is doing real work here: the research base is broad enough in trial count and independent enough in funding to reach four dots on those criteria alone. It sits at three because the trials do not agree. Reduces excessive sleepiness in approved sleep disorders Strong Supported Improves cognition in rested, healthy adults Moderate Mixed A third situation is worth separating out: countering the deficit caused by lost sleep, which is a different achievement from raising a rested person above their own baseline. The evidence there is better, and modafinil does sustain performance through sleep deprivation. We describe it here rather than grading it, because the trials are scattered across designs and outcome measures and no review reports a poolable participant total — and a claim we cannot count is a claim we will not put dots on. ## Safety and unknowns - Serious rash The label carries a warning for rare but life-threatening skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms. Nearly all reported cases began **within one to five weeks of starting**, and the instruction is to stop at the first sign of a rash unless it is clearly unrelated.[3](#c3) - It can make hormonal contraception fail Modafinil induces CYP3A4/5, which increases clearance of steroidal contraceptives and lowers their systemic exposure. The label recommends alternative or additional contraception during treatment **and for one month after stopping**.[3](#c3) This is the least known and most consequential interaction on the label, and it is routinely absent from the online discussion of modafinil as a study aid. - Common effects Headache is the most frequent, along with nausea, nervousness, insomnia and reduced appetite. Sleep disruption is dose- and timing-dependent, and the drug's long half-life is why late dosing costs a night. - Controlled substance Schedule IV in the United States.[3](#c3) Dependence potential is lower than for classical stimulants but is not zero, and possession without a prescription is unlawful. - Long-term use in healthy people Unstudied. The safety record comes from patients with sleep disorders taking it under supervision for a diagnosed condition, not from healthy adults taking it to work longer. ## How the grade was reached #### Evidence strength — Moderate, criteria checked Qualifying randomised placebo-controlled trialsmany ✓ Independent groups reportingmultiple academic ✓ Total participants200+ ✓ Published systematic reviewyes ✓ Trials with 100+ participants eachmostly small crossovers ✗ Verdict is Supported or Not supported, not MixedMixed ✗ The Mixed verdict is the binding cap. Even if the trials were larger, unresolved disagreement between them would hold this claim at Moderate until something settles it. ## Bottom line Modafinil works for the sleep disorders it is licensed to treat, and it helps sleep-deprived people recover ground they have lost. Neither of those is in dispute. For a rested person hoping to think better than they otherwise would, the evidence is real but inconsistent: little on simple tasks, more reliable on complex ones, and tangled up with the drug's clear effects on mood and motivation. The honest summary is that it makes hard work feel more tractable, which is not the same as making you sharper. It is a prescription controlled substance with a rash warning that requires stopping at first sign, and it can quietly defeat hormonal contraception for a month after the last dose. nootropics grade-moderate verdict-mixed modafinil ## Sources 1. Battleday RM, Brem AK. Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: a systematic review. *European Neuropsychopharmacology*. 2015;25(11):1865–1881\. PMID 26381811\. [pubmed.ncbi.nlm.nih.gov/26381811](https://pubmed.ncbi.nlm.nih.gov/26381811/?ref=compoundcodex.org) 2. Battleday RM, Brem AK. Authors' response. *European Neuropsychopharmacology*. 2016;26(2):394–395\. PMID 26718790\. Response to critique of the review above. [pubmed.ncbi.nlm.nih.gov/26718790](https://pubmed.ncbi.nlm.nih.gov/26718790/?ref=compoundcodex.org) 3. US Food and Drug Administration. PROVIGIL (modafinil) prescribing information. Schedule IV; serious rash warning; CYP3A4 induction and reduced contraceptive effectiveness. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3b8d1c32-dac9-50e6-e063-6394a90aa5a5&ref=compoundcodex.org) 4. University of Oxford. Review of 'smart drug' shows modafinil does enhance cognition. 2015\. The press coverage that shaped public understanding of the review. [ox.ac.uk](https://www.ox.ac.uk/news/2015-08-20-review-%E2%80%98smart-drug%E2%80%99-shows-modafinil-does-enhance-cognition?ref=compoundcodex.org) 5. Drugs.com. Modafinil monograph for professionals. Indications, interactions and adverse effects. [drugs.com](https://www.drugs.com/monograph/modafinil.html?ref=compoundcodex.org) 6. US Food and Drug Administration. Modafinil tablets label, C-IV. Initial US approval 1998\. [accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda%5Fdocs/label/2015/020717s037s038lbl.pdf?ref=compoundcodex.org) **The Compound Codex** — marks are assigned under the [public editorial standards](https://compoundcodex.org/editorial-standards/) in force on the day of publication, and every mark is [open to challenge](https://compoundcodex.org/challenge/). Informational only. Nothing here is medical advice, and nothing here endorses the use of any compound discussed. Modafinil is a prescription-only controlled substance. © 2026 The Compound Codex · Every claim cited, none of them prescriptive.